Akoya Biosciences, INC Form 4 insider transactions

Akoya Biosciences Director Scott Mendel reported the disposition of all his common stock and stock options in Akoya Biosciences, Inc. on July 8, 2025, as a result of the company's merger with Quanterix Corporation.

Akoya Biosciences, Inc. Chief Business Officer, Niro Ramachandran, Ph.D., converted his equity holdings into Quanterix Corporation shares and cash following the merger of Akoya into a wholly-owned subsidiary of Quanterix.

Akoya Biosciences, Inc. President and CEO Brian McKelligon reported the final disposition of his common stock and derivative securities in Akoya Biosciences following its merger with Quanterix Corporation on July 8, 2025.

Jennifer Kamocsay, Chief Legal Officer of Akoya Biosciences, Inc., reported the disposition of common stock and employee stock options as Akoya Biosciences merged into a wholly-owned subsidiary of Quanterix Corporation on July 8, 2025.

Akoya Biosciences, Inc. CFO John Frederick Ek has reported the complete disposition of his beneficial ownership in Akoya common stock and stock options, effective July 8, 2025, as a result of the company's merger with Quanterix Corporation.

Akoya Biosciences' Chief Clinical Officer, Pascal Bamford, reported the disposition of common stock and termination of stock options and conversion of restricted stock units as a result of the company's merger with Quanterix Corporation on July 8, 2025.

Akoya Biosciences Director Matthew Winkler has disposed of all his common stock and stock options in Akoya Biosciences, Inc. following its merger with Quanterix Corporation, effective July 8, 2025.

Robert G. Shepler's stock options in Akoya Biosciences, Inc. were terminated for no consideration following the company's merger with Quanterix Corporation.

A director of Akoya Biosciences, Inc. disposed of all stock options as part of the company's merger with Quanterix Corporation, effective July 8, 2025.

Akoya Biosciences, Inc. has completed its merger with Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, resulting in Akoya becoming a Quanterix subsidiary and the conversion of Akoya shares into cash and Quanterix stock.

Akoya Biosciences, Inc. has completed its merger with Quanterix Corporation, resulting in the disposition of common stock and termination of certain stock options for Director Myla Lai-Goldman.

Akoya Biosciences, Inc. announced that Party A has withdrawn its unsolicited all-cash acquisition proposal, leading Akoya's Board to reaffirm its commitment to the previously announced merger with Quanterix Corporation.

Akoya Biosciences' Chief Clinical Officer, Pascal Bamford, reported the scheduled disposition of 670 shares of common stock to cover tax obligations related to a restricted stock unit award.

Akoya Biosciences announced its Q1 2025 financial results, highlighting revenue of $16.6 million and progress in spatial biology adoption, while also noting a pending acquisition by Quanterix Corporation.

Quanterix reported a 5% decrease in revenue for Q1 2025, alongside announcing a cost reduction plan and providing updates on the Akoya Biosciences merger.

Quanterix and Akoya Biosciences have revised their merger agreement, decreasing the number of Quanterix shares to be issued and adjusting the cash consideration.

Quanterix and Akoya Biosciences have amended their merger agreement, reducing the number of Quanterix shares to be issued and increasing the cash consideration for Akoya shareholders.

Akoya Biosciences enters into a securities purchase agreement with Quanterix for up to $30 million in convertible notes to support its financial obligations pending a potential merger.

Quanterix Corporation will provide Akoya Biosciences with up to $30 million in convertible note financing, contingent on certain milestones and the potential termination of their merger agreement.

CFO John Frederick Ek reports disposition of Akoya Biosciences shares to cover taxes related to a restricted stock unit award.

Brian McKelligon, CEO of Akoya Biosciences, reports disposition of shares to cover taxes on a previously granted restricted stock unit award.

Niro Ramachandran, Chief Business Officer of Akoya Biosciences, disposed of 2,310 shares to cover taxes related to a restricted stock unit award.

Quanterix's CEO addresses investor concerns regarding the proposed acquisition of Akoya Biosciences, emphasizing long-term value creation and recurring revenue opportunities despite market headwinds.

Quanterix reports 11% revenue growth for Q4 2024 and highlights the planned acquisition of Akoya Biosciences to expand its market presence.

Jennifer Kamocsay, Chief Legal Officer of Akoya Biosciences, reports the withholding of shares to cover taxes on restricted stock unit awards.

CFO of Akoya Biosciences, John Frederick Ek, reports disposition of shares to cover taxes on a restricted stock unit award.

Chief Clinical Officer Pascal Bamford of Akoya Biosciences reports the withholding of shares to cover taxes on restricted stock unit awards.

Niro Ramachandran, Chief Business Officer of Akoya Biosciences, reports the withholding of shares to cover taxes on restricted stock unit awards.

Brian McKelligon, CEO of Akoya Biosciences, reports disposition of shares to cover tax obligations related to restricted stock unit awards.

Quanterix emphasizes the strategic and financial advantages of acquiring Akoya Biosciences, projecting significant market expansion and synergy generation, while addressing director nominations from Kent Lake Partners.